U.S. Markets closed

Why Dynavax Technologies Stock Fell 51% in 2018

George Budwell, The Motley Fool

What happened

By and large, biotech stocks had a forgettable 2018, and none more so than Dynavax Technologies (NASDAQ: DVAX) . Despite the long-awaited commercial launch of Dynavax's hepatitis B vaccine, Heplisav-B, the stock lost a staggering 51% of its value last year, according to data from S&P Global Market Intelligence .

Dynavax was thus one of the worst-performing biotech stocks among companies with a product on the market in 2018.

Chalkboard chart with a downward trending arrow.

Image source: Getty Images.

So what

Why was Dynavax's stock singled out for such harsh treatment last year? It all boils down to Heplisav-B's commercial performance. Over the first nine months of the year, the vaccine generated an anemic $2.9 million in net revenue for the company -- a figure that underwhelmed Wall Street, to put it mildly. Heplisav-B, after all, was championed, prior to its launch, as the heir apparent to GlaxoSmithKline 's aging hepatitis B vaccine Engerix-B, thanks to its pronounced dosing and potency advantages over the current market share leader .

Now what

Heplisav-B's slow commercial launch, though, certainly shouldn't be viewed as a failure -- or even as a harbinger of things to come. The long and short of it is that Dynavax had to build a commercial infrastructure from the ground up to launch Heplisav-B on its own and that process takes time -- especially for a company with a rather limited budget and other pressing capital allocation needs.

Fortunately, Dynavax's hard work appears to be paying off. At the recent J.P. Morgan Healthcare Conference , the company announced that Heplisav-B's fourth-quarter sales came in at a respectable $3.7 million for the three-month period. The vaccine's commercial launch, therefore, appears to be gaining traction. And if so, Dynavax may have what it takes to mount a comeback in 2019.

More From The Motley Fool

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .